A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthritis

Recruiting now · Phase 1

Conditions studied: Rheumatoid Arthritis

In brief

The purpose of this study is to determine the safety and tolerability of plamotamab in patients with rheumatoid arthritis. Participants will be given XmAb13676 subcutaneously (SC) by injection under the skin.

Key facts

Study ID

NCT07230353

Run by

Xencor, Inc.

People needed

68

Starts

2025-10-21

Expected to finish

2028-06-01

Last updated by the study team

2026-08-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Major surgery within 12 weeks prior to screening or planned within 12 months after dosing
• Recurrent infections or active clinically significant infection
• Active or untreated latent tuberculosis
• Cancer or history of cancer or lymphoproliferative disease within the previous 5 years
• Uncontrolled cardiovascular, pulmonary, renal, hepatic, endocrine, or gastrointestinal disease
• Note: Additional, more specific inclusion/exclusion criteria are defined in the protocol.

Where it is running

• Xencor Investigative Site — Tbilisi, Georgia (enrolling)
• Xencor Investigative Site — Chisinau, Moldova (enrolling)
• Xencor Investigative Site — Auckland, New Zealand (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.